Global Cough Hypersensitivity Syndrome Market, By Drug Class (Inhales Corticosteroids, Antitussive Agents, Short-acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Others), Route of Administration (Oral, Inhalation, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The cough reflex is an important protective mechanism against aspiration, but it can become hypersensitive if it is mismanaged. Chronic cough, in reality, is a serious medical condition with a high rate of morbidity. Cough hypersensitivity syndrome has now been given a unified paradigm. It's a clinical entity in which chronic cough is the primary symptom, regardless of the underlying disease. Although it is still a theory, new research reveals that abnormal neurophysiology is the most common cause of this illness. Our understanding of cough mechanisms has evolved in tandem with this paradigm shift in recent decades, allowing us to take even more strides forward in the future.
Data Bridge Market Research analyses that the cough hypersensitivity syndrome market was valued at USD 8.31 billion in 2021 and is expected to reach USD 13.15 billion by 2029, registering a CAGR of 5.90% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Inhales Corticosteroids, Antitussive Agents, Short-acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Others), Route of Administration (Oral, Inhalation, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Akorn, Incorporated (US), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Prestige Consumer Healthcare Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (U.S.), Almirall, S.A (Spain), Zenomed Healthcare Private Limited (India), Cadila Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
Cough is the most common sickness worldwide, according to the WHO. The treatment algorithm is shifting away from small compounds and toward biologics and natural treatments. Combination therapy have become increasingly common in recent years. Clinical trials are underway for the majority of industry-sponsored products. Cough hypersensitivity syndrome has a severe impact on patients' lives, including sleep disruption, vomiting, light-headedness, and even rib fractures. Infections, gastroesophageal reflux disease (GERD), asthma, and other factors can all contribute to it. Companies in the cough hypersensitivity syndrome treatment market are boosting the availability of babapentin and pregabalin, which are GABA-related chemicals that operate as neuromodulators for the treatment of neuropathic pain and epilepsy, because chronic cough produces greater bodily discomfort. Gabapentin has been reported to be well tolerated in placebo-controlled trials for the treatment of refractory persistent cough.
Cough Hypersensitivity Syndrome Market Dynamics
Drivers
- Increasing prevalence of chronic respiratory diseases
The rising prevalence of chronic respiratory diseases is anticipated to drive the cough hypersensitivity syndrome market's growth. Cough is a prevalent illness that affects millions of individuals throughout the world. Globally, the prevalence of chronic respiratory disorders is increasing, resulting in an increase in chronic cough problems. As a result, the expanding disease burden provides a bright future for the global market. Although some research suggest that other factors, such as asthma, smoking, a hot and humid atmosphere, and viral or bacterial illness, may increase the likelihood of getting cough.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of cough hypersensitivity syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics. Healthcare industries are investing in opiates and GABA (gamma-aminobutyric acid)-related substances to help people with cough hypersensitivity. To treat chronic intractable cough, opiates are excellent cough suppressants and have antitussive actions. Similarly, corporations are expanding their tramadol production capabilities, an opioid prescription with a chemical makeup comparable to codeine medicines.
Furthermore, surging geriatric population and sedentary lifestyle of people such as high addiction of smoking will result in the expansion of cough hypersensitivity syndrome market. Along with this, favourable reimbursement policies and rising number of government initiatives to spread awareness will enhance the growth rate of the market.
Opportunities
- Rising number of clinical trials
Over the forecast period, the cough hypersensitivity syndrome market is expected to develop due to an increase in the number of clinical trials for the treatment of cough hypersensitivity syndrome. This is anticipated to boost the new market opportunities. The recent success of a P2X3 receptor antagonist in randomized clinical trials is the first major advancement in cough treatments in 30 years; it finally gives a method for treating persistent cough as well as a useful tool for unravelling the mechanism underlying cough hypersensitivity.
Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the cough hypersensitivity syndrome market growth.
Restraints/Challenges
On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the cough hypersensitivity syndrome market. Additionally, lack of awareness among people and inefficiency of drugs along with its adverse effects will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This cough hypersensitivity syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cough hypersensitivity syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Cough hypersensitivity syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cough Hypersensitivity Syndrome Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The cough hypersensitivity syndrome market was hampered by the supply chain slowness. On the bright side, the cough hypersensitivity syndrome market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.
Global Cough Hypersensitivity Syndrome Market Scope
The cough hypersensitivity syndrome market is segmented on the basis of drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Inhales Corticosteroids
- Antitussive Agents
- Short-acting Beta-2 Agonists
- Anticholinergics
- Proton Pump Inhibitors
- Antihistamines
- Others
Route of Administration
- Oral
- Inhalation
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Cough Hypersensitivity Syndrome Market Regional Analysis/Insights
The cough hypersensitivity syndrome market is analyzed and market size insights and trends are provided by country, drug class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the cough hypersensitivity syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the cough hypersensitivity syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of respiratory disorders and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to surging number of population in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cough Hypersensitivity Syndrome Market Share Analysis
The cough hypersensitivity syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cough hypersensitivity syndrome market.
Some of the major players operating in the cough hypersensitivity syndrome market are:
- Akorn, Incorporated (U.S.)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Prestige Consumer Healthcare Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (U.S.)
- Almirall, S.A (Spain)
- Zenomed Healthcare Private Limited (India)
- Cadila Pharmaceuticals (India)
SKU-